alanine has been researched along with Glycogen Storage Disease Type II in 6 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Glycogen Storage Disease Type II: An autosomal recessively inherited glycogen storage disease caused by GLUCAN 1,4-ALPHA-GLUCOSIDASE deficiency. Large amounts of GLYCOGEN accumulate in the LYSOSOMES of skeletal muscle (MUSCLE, SKELETAL); HEART; LIVER; SPINAL CORD; and BRAIN. Three forms have been described: infantile, childhood, and adult. The infantile form is fatal in infancy and presents with hypotonia and a hypertrophic cardiomyopathy (CARDIOMYOPATHY, HYPERTROPHIC). The childhood form usually presents in the second year of life with proximal weakness and respiratory symptoms. The adult form consists of a slowly progressive proximal myopathy. (From Muscle Nerve 1995;3:S61-9; Menkes, Textbook of Child Neurology, 5th ed, pp73-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report a male with late infantile glycogen storage disease type II (Pompe's disease) who presented at 12 months of age with muscular hypotonia and developmental delay." | 5.31 | L-alanine supplementation in late infantile glycogen storage disease type II. ( Bodamer, OA; Haas, D; Hermans, MM; Hoffmann, GF; Reuser, AJ, 2002) |
| "Late-onset acid maltase deficiency or glycogen storage disease type II (GSD II) is a rare disorder of intralysosomal glycogen metabolism, resulting in progressive myopathy that is secondary to increased muscle protein breakdown." | 2.40 | Dietary treatment in late-onset acid maltase deficiency. ( Bodamer, OA; Halliday, D; Leonard, JV, 1997) |
| "F." | 1.72 | L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report. ( Banderali, G; Cefalo, G; Dionigi, AR; Ercoli, V; Paci, S; Piotto, M; Rovelli, V; Salvatici, E; Scopari, A; Zuvadelli, J, 2022) |
| "We report a male with late infantile glycogen storage disease type II (Pompe's disease) who presented at 12 months of age with muscular hypotonia and developmental delay." | 1.31 | L-alanine supplementation in late infantile glycogen storage disease type II. ( Bodamer, OA; Haas, D; Hermans, MM; Hoffmann, GF; Reuser, AJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Rovelli, V | 1 |
| Zuvadelli, J | 1 |
| Piotto, M | 1 |
| Scopari, A | 1 |
| Dionigi, AR | 1 |
| Ercoli, V | 1 |
| Paci, S | 1 |
| Cefalo, G | 1 |
| Salvatici, E | 1 |
| Banderali, G | 1 |
| Bodamer, OA | 3 |
| Haas, D | 1 |
| Hermans, MM | 1 |
| Reuser, AJ | 1 |
| Hoffmann, GF | 1 |
| Mundy, HR | 1 |
| Williams, JE | 1 |
| Cousins, AJ | 1 |
| Lee, PJ | 1 |
| Leonard, JV | 2 |
| Halliday, D | 2 |
| Umpleby, AM | 1 |
| Trend, PS | 1 |
| Chubb, D | 1 |
| Conaglen, JV | 1 |
| Williams, CD | 1 |
| Hesp, R | 1 |
| Scobie, IN | 1 |
| Wiles, CM | 1 |
| Spencer, G | 1 |
| Sönksen, PH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Effectiveness of Resistance Exercise Training in Patients With Late Onset Pompe Disease- A Pilot Study[NCT02654886] | 10 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| A Pilot Study of Diet and Exercise Therapy in Pompe Disease[NCT02363153] | 2 participants (Actual) | Interventional | 2017-11-06 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alanine and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
Dietary treatment in late-onset acid maltase deficiency.
Topics: Adolescent; Adult; Age of Onset; Alanine; Energy Metabolism; Glucose; Glycogen Storage Disease Type | 1997 |
Dietary treatment in late-onset acid maltase deficiency.
Topics: Adolescent; Adult; Age of Onset; Alanine; Energy Metabolism; Glucose; Glycogen Storage Disease Type | 1997 |
Dietary treatment in late-onset acid maltase deficiency.
Topics: Adolescent; Adult; Age of Onset; Alanine; Energy Metabolism; Glucose; Glycogen Storage Disease Type | 1997 |
Dietary treatment in late-onset acid maltase deficiency.
Topics: Adolescent; Adult; Age of Onset; Alanine; Energy Metabolism; Glucose; Glycogen Storage Disease Type | 1997 |
2 trials available for alanine and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
The effect of L-alanine therapy in a patient with adult onset glycogen storage disease type II.
Topics: Aged; Alanine; Body Mass Index; Cross-Over Studies; Double-Blind Method; Female; Glycogen Storage Di | 2006 |
The effect of a high protein diet on leucine and alanine turnover in acid maltase deficiency.
Topics: Adult; Alanine; alpha-Glucosidases; Clinical Trials as Topic; Dietary Proteins; Female; Follow-Up St | 1989 |
3 other studies available for alanine and Glycogen Storage Disease Type II
| Article | Year |
|---|---|
L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.
Topics: Alanine; alpha-Glucosidases; Dietary Supplements; Enzyme Replacement Therapy; Female; Glycogen Stora | 2022 |
L-alanine supplementation in late infantile glycogen storage disease type II.
Topics: Administration, Oral; Alanine; Cardiomyopathies; Dietary Supplements; Glycogen Storage Disease Type | 2002 |
The effects of l-alanine supplementation in late-onset glycogen storage disease type II.
Topics: Adolescent; Adult; Alanine; Energy Metabolism; Female; Glucose; Glycogen Storage Disease Type II; Hu | 2000 |